These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
246 related articles for article (PubMed ID: 23170062)
1. Review: tauopathy in the retina and optic nerve: does it shadow pathological changes in the brain? Ho WL; Leung Y; Tsang AW; So KF; Chiu K; Chang RC Mol Vis; 2012; 18():2700-10. PubMed ID: 23170062 [TBL] [Abstract][Full Text] [Related]
2. Optic nerve thinning and neurosensory retinal degeneration in the rTg4510 mouse model of frontotemporal dementia. Harrison IF; Whitaker R; Bertelli PM; O'Callaghan JM; Csincsik L; Bocchetta M; Ma D; Fisher A; Ahmed Z; Murray TK; O'Neill MJ; Rohrer JD; Lythgoe MF; Lengyel I Acta Neuropathol Commun; 2019 Jan; 7(1):4. PubMed ID: 30616676 [TBL] [Abstract][Full Text] [Related]
3. Tau Seeding Mouse Models with Patient Brain-Derived Aggregates. Robert A; Schöll M; Vogels T Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34200180 [TBL] [Abstract][Full Text] [Related]
4. Molecular Pathogenesis of the Tauopathies. Götz J; Halliday G; Nisbet RM Annu Rev Pathol; 2019 Jan; 14():239-261. PubMed ID: 30355155 [TBL] [Abstract][Full Text] [Related]
5. The innate immune response in tauopathies. Johnson AM; Lukens JR Eur J Immunol; 2023 Jun; 53(6):e2250266. PubMed ID: 36932726 [TBL] [Abstract][Full Text] [Related]
6. Microglial activation arises after aggregation of phosphorylated-tau in a neuron-specific P301S tauopathy mouse model. van Olst L; Verhaege D; Franssen M; Kamermans A; Roucourt B; Carmans S; Ytebrouck E; van der Pol SMA; Wever D; Popovic M; Vandenbroucke RE; Sobrino T; Schouten M; de Vries HE Neurobiol Aging; 2020 May; 89():89-98. PubMed ID: 32008854 [TBL] [Abstract][Full Text] [Related]
7. Evidence for accelerated tauopathy in the retina of transgenic P301S tau mice exposed to repetitive mild traumatic brain injury. Xu L; Ryu J; Nguyen JV; Arena J; Rha E; Vranis P; Hitt D; Marsh-Armstrong N; Koliatsos VE Exp Neurol; 2015 Nov; 273():168-76. PubMed ID: 26311071 [TBL] [Abstract][Full Text] [Related]
8. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics. Rosenmann H; Grigoriadis N; Eldar-Levy H; Avital A; Rozenstein L; Touloumi O; Behar L; Ben-Hur T; Avraham Y; Berry E; Segal M; Ginzburg I; Abramsky O Exp Neurol; 2008 Jul; 212(1):71-84. PubMed ID: 18490011 [TBL] [Abstract][Full Text] [Related]
9. The use of mouse models to study cell-to-cell transmission of pathological tau. Narasimhan S; Lee VMY Methods Cell Biol; 2017; 141():287-305. PubMed ID: 28882308 [TBL] [Abstract][Full Text] [Related]
12. Targeting tauopathy with engineered tau-degrading intrabodies. Gallardo G; Wong CH; Ricardez SM; Mann CN; Lin KH; Leyns CEG; Jiang H; Holtzman DM Mol Neurodegener; 2019 Oct; 14(1):38. PubMed ID: 31640765 [TBL] [Abstract][Full Text] [Related]
13. Long-term in vivo imaging of fibrillar tau in the retina of P301S transgenic mice. Schön C; Hoffmann NA; Ochs SM; Burgold S; Filser S; Steinbach S; Seeliger MW; Arzberger T; Goedert M; Kretzschmar HA; Schmidt B; Herms J PLoS One; 2012; 7(12):e53547. PubMed ID: 23300938 [TBL] [Abstract][Full Text] [Related]
14. Experimental Models of Tauopathy - From Mechanisms to Therapies. Götz JJ; Götz J Adv Exp Med Biol; 2019; 1184():381-391. PubMed ID: 32096051 [TBL] [Abstract][Full Text] [Related]
15. Combining P301L and S320F tau variants produces a novel accelerated model of tauopathy. Koller EJ; Gonzalez De La Cruz E; Machula T; Ibanez KR; Lin WL; Williams T; Riffe CJ; Ryu D; Strang KH; Liu X; Janus C; Golde TE; Dickson D; Giasson BI; Chakrabarty P Hum Mol Genet; 2019 Oct; 28(19):3255-3269. PubMed ID: 31261380 [TBL] [Abstract][Full Text] [Related]
16. Tau accumulation in the retina promotes early neuronal dysfunction and precedes brain pathology in a mouse model of Alzheimer's disease. Chiasseu M; Alarcon-Martinez L; Belforte N; Quintero H; Dotigny F; Destroismaisons L; Vande Velde C; Panayi F; Louis C; Di Polo A Mol Neurodegener; 2017 Aug; 12(1):58. PubMed ID: 28774322 [TBL] [Abstract][Full Text] [Related]
18. Tauopathies and tau oligomers. Takashima A J Alzheimers Dis; 2013; 37(3):565-8. PubMed ID: 23948895 [TBL] [Abstract][Full Text] [Related]
19. Tau-mediated dysregulation of RNA: Evidence for a common molecular mechanism of toxicity in frontotemporal dementia and other tauopathies. Koren SA; Galvis-Escobar S; Abisambra JF Neurobiol Dis; 2020 Jul; 141():104939. PubMed ID: 32413399 [TBL] [Abstract][Full Text] [Related]
20. Tau oligomer induced HMGB1 release contributes to cellular senescence and neuropathology linked to Alzheimer's disease and frontotemporal dementia. Gaikwad S; Puangmalai N; Bittar A; Montalbano M; Garcia S; McAllen S; Bhatt N; Sonawane M; Sengupta U; Kayed R Cell Rep; 2021 Jul; 36(3):109419. PubMed ID: 34289368 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]